Pomalyst® (pomalidomide): New important advice to minimise the risk of serious hepatotoxicity, interstitial lung disease and cardiac failure

Celgene Pte Ltd, Singapore, would like to inform healthcare professionals of important new safety information regarding Pomalyst® (pomalidomide). A European review concluded that pomalidomide can cause serious hepatotoxicity (acute hepatitis), interstitial lung disease and cardiac failure. The safety review was based on data from clinical trials, reports from clinical practice as well as published case reports. The local Package Insert and Patient Information Leaflet for Pomalyst® will be updated to include the above-mentioned newly identified risks. Please refer to the letter for more information.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.